The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition
Open accessAbstract
Background: The role of both microglial activation and alpha-synuclein deposition in Parkinson's disease remain unclear. We have tested the hypothesis that if microglia play a primary role in Parkinson's disease pathogenesis, the microglial "activated" phenotype should be associated with histopathological and/or clinical features of the disease. Methods: We have examined microglial MHC class II expression, a widely used marker of microglial activation, the occurrence of CD68-positive phagocytes and alpha-synuclein immunoreactivity in post-mortem human substantia nigra affected by idiopathic Parkinson's disease (PD). Using semi-quantitative severity ratings, we have examined the relationship between microglial activation, alpha-synuclein deposition, classical neuropathological criteria for PD, subtype of the disease and clinical course. Results: While we did not observe an association between microglial MHC class II expression and clinical parameters, we did find a correlation between disease duration and the macrophage marker CD68 which is expressed by phagocytic microglia. In addition, we observed a significant correlation between the degree of MHC class II expression and alpha-synuclein deposition in the substantia nigra in PD. Conclusion: While microglia appeared to respond to alpha-synuclein deposition, MHC class II antigen expression by microglia in the substantia nigra cannot be used as an indicator of clinical PD severity or disease progression. In addition, a contributory or even causative role for microglia in the neuronal loss associated with PD as suggested by some authors seems unlikely. Our data further suggest that an assessment of microglial activation in the aged brain on the basis of immunohistochemistry for MHC class II antigens alone should be done with caution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dysregulation of microglia functions contribute to the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD) (6–8), Parkinson’s disease (PD) (9–12) and Huntington’s disease (HD) (13–15).”
From An environment-dependent transcriptional network specifies human microglia identity (2017) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Microglia accumulate near α-synuclein deposits and become proinflammatory in a manner dependent on receptors that also bind Aβ, such as CD36 and TLR263–65.”
From Microglia in neurodegeneration (2018) · cites this paper as [63]
In the citing paper
“Microglia also phagocytose α-synuclein, the constituent protein of Lewy bodies in Parkinson’s and Lewy Body dementias, and become pro-inflammatory in the process, expressing cytokines (IL1β, IL6, TNFα), reactive oxygen species (ROS) and prostaglandin synthesising cyclooxygenase 2 (COX2) [24,25,26].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Self-citationMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Liu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791
Research works printed but not linked: 1
- Graeber MB: Glial inflammation in neurodegenerative diseases. 8th Annual Congress of the British Society for Immunology, Harrogate, 5–8 December 2000, Immunology. 2000, Oxford: Blackwells, Abstract, Supplement
Cited by
Sorted by citations
Items 301–400 of 416
Challenges in molecular imaging of Parkinson’s disease: A brief overview
Kassiou, M., Banati, R. B., Holsinger, R. M. D., & Meikle, S. R. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.08.006 · Cited by 8
Torrecillas-López, M., Rivero‐Pino, F., Trigo, P., Toscano, R., la Rosa, T. G., Villanueva-Lazo, A., Millán-Linares, M. C., la Paz, S. M., & Claro, C. (2024) · Food & Function · doi:10.1039/d4fo03167a · Cited by 7
Polydopamine nanoparticles as immunomodulators: inhibition of M1 microglial polarization
Ceccarelli, M. C., Lai, L., Carmignani, A., Battaglini, M., & Ciofani, G. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1672520 · Cited by 7
Neuroglia in neurodegeneration: Alzheimer, Parkinson, and Huntington disease
Lim, D., Matute, C., Cavaliere, F., & Verkhratsky, A. (2025) · Handbook of Clinical Neurology · doi:10.1016/b978-0-443-19102-2.00012-0 · Cited by 8
Choy, Y., Hong, S.-Y., Pack, S.-J., Woo, R., Baik, T., & Song, D. (2015) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2015.03.003 · Cited by 7
Immunological aspects of Parkinson's disease
Belova, O. V., Arefieva, T. I., & Moskvina, S. N. (2020) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2020120021110 · Cited by 8
Liang, L., Fulton, R. E., Bradshaw‐Pierce, E. L., Pearson-Smith, J. N., Day, B. J., & Patel, M. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000229 · Cited by 7
Rangasamy, S. B., Dutta, D., Mondal, S., Majumder, M., Dasarathi, S., Chandra, G., & Pahan, K. (2022) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2022-0005 · Cited by 7
Nam, M., Shin, H. A., Han, J.-H., Park, D.-W., & Rhim, H. (2013) · Brain Research · doi:10.1016/j.brainres.2013.02.005 · Cited by 7
Ray, A., Kambali, M., & Ravindranath, V. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6602 · Cited by 6
α‐Synuclein activates innate immunity but suppresses interferon‐γ expression in murine astrocytes
Wang, J., Chen, Z., Walston, J. D., Gao, P., Gao, M., & Leng, S. X. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13956 · Cited by 6
Oxidative Stress in Parkinson’s Disease: Role in Neurodegeneration and Targets for Therapeutics
Banerjee, R., Kaidery, N. A., & Thomas, B. (2015) · ACS symposium series · doi:10.1021/bk-2015-1200.ch005 · Cited by 7
Moro, A. S., Balestrucci, C., Cozzi, A., Santambrogio, P., & Levi, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136197 · Cited by 5
Neuroinflammation as a Potential Mechanism Underlying Parkinsons Disease
Cebrián, C., & Sulzer, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803783-6.00008-0 · Cited by 7
Booth, S., & Ko, J. H. (2024) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-024-00842-9 · Cited by 4
Tönges, L., Metzdorf, J., & Zella, S. M. A. (2018) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0044-101608 · Cited by 6
NPY and chronic neurodegenerative disease
Colton, C. A., & Vitek, M. P. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7417-9_17 · Cited by 4
Sarkissian, J. S., Chavushyan, V. A., Meliksetyan, I. B., Poghosyan, М. V., Avakyan, Z. E., Mkrtchian, H., Kamenetsky, V., Abrahamyan, D. O., & Heratsi, M. (2007) · Cited by 4
Li, J., Jian, L., Huang, J., Xiong, N., & Wang, T. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1753728 · Cited by 3
Bang, Y., Moon, S.-H., Lee, S., & Choi, H. J. (2024) · Drug Targets and Therapeutics · doi:10.58502/dtt.24.0030 · Cited by 3
HLA Class Ib and MICA/MICB Expression in Human Tissues and Cell Types: Reshuffling Immune Players
Abi‐Rached, L., Faux, P., Paganini, J., Chiaroni, J., Pontarotti, P., & Cristofaro, J. D. (2025) · HLA · doi:10.1111/tan.70390 · Cited by 2
Modeling synucleinopathies in rodents
Janer, A. B., Vonck, E., & Baekelandt, V. (2021) · International review of movement disorders · doi:10.1016/bs.irmvd.2021.09.001 · Cited by 3
Neuroprotection Versus Neurotoxicity
Biber, K. P. H., & Block, M. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1429-6_6 · Cited by 3
Microglial activation in a mouse model of α-synuclein overexpression
Maguire‐Zeiss, K. A., Su, X., & Federoff, H. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00040-3 · Cited by 3
Role of CD4+ T Cells in Parkinson's Disease
Ghanta, M. K., Nuthalapati, P., Merchant, N., Chenchula, S., Hussain, F., Ak, A. K., & Bhaskar, L. V. (2022) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2023047372 · Cited by 3
Parkinson's Disease and Amyotrophic Lateral Sclerosis
Mosley, R. L., Reynolds, A. D., Stone, D. K., & Gendelman, H. E. (2008) · Springer eBooks · doi:10.1007/978-0-387-72573-4_44 · Cited by 3
Chakraborty, R., & Zurzolo, C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.13.519450 · Cited by 3
Mackie, P. M., Koshy, J. M., Bhogade, M., Hammoor, T., Hachmeister, W., Lloyd, G. M., Paterno, G., Bolen, M. L., Merchak, A. R., Tansey, M. G., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68641-8 · Cited by 9
Tchung, A., Even, A., & Trudeau, L. (2026) · Trends in Neurosciences · doi:10.1016/j.tins.2026.02.003 · Cited by 3
O-GlcNAcylation regulates microglial neuroinflammation in Parkinson’s disease
Kim, D. Y., Kim, S.-M., Lee, C. J., & Han, I. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01319-6 · Cited by 2
DYRK1A and Parkinson’s disease, facts and hypotheses
Meijer, L., Lindberg, M. F., Hogrel, G., & Khor, B. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107379 · Cited by 2
Chief Role of Neuroinflammation and Oxidative Stress in Brain Disorders
Zafar, S. (2023) · Food bioactive ingredients · doi:10.1007/978-3-031-41188-5_5 · Cited by 2
Functional foods and Parkinson's disease: A focus on omega-3 fatty acids
Li, P., & Song, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91747-6.00007-x · Cited by 2
Biomarkers for Neurodegenerative Diseases
Abdelmoaty, M. M., Lu, E., & Foster, E. G. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_44 · Cited by 2
Janer, A. B., Acker, E. V., Vonck, E., Plessers, D., Rosada, F., den Haute, C. V., Baekelandt, V., & Peelaerts, W. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01170-1 · Cited by 2
Mancinelli, A. M., Vichich, J. M., Zinnen, A. D., Hugon, A. M., Bondarenko, V., Metzger, J. M., Simmons, H. A., Golos, T. G., & Emborg, M. E. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s337549 · Cited by 2
Alpha-Synuclein and the Immune Response in Parkinson’s Disease
Roodveldt, C., Labrador‐Garrido, A., Izquierdo, G., & Pozo, D. (2011) · InTech eBooks · doi:10.5772/17417 · Cited by 3
Immunotherapies for Movement Disorders: Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Schutt, C. R., Gendelman, H. E., & Mosley, R. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_46 · Cited by 2
Role of the Innate and Adaptive Immune System in the Pathogenesis of PD
Kannarkat, G. T., & Tansey, M. G. (2014) · Springer eBooks · doi:10.1007/978-3-319-08046-8_3 · Cited by 2
Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases
Olson, K. E., Mosley, R. L., & Gendelman, H. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-33946-3_8 · Cited by 2
Kline, E. M., Jernigan, J. E., Scharer, C. D., Maurer, J., Hicks, S. L., Herrick, M. K., Wallings, R. L., Kelly, S. D., Chang, J., Menees, K. B., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-95679-3 · Cited by 1
Wang, Y.-C., Huang, L.-Y., Yan-Fu, Xiong, S.-Y., Wang, Z.-T., Tan, C., & Tan, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06729-3 · Cited by 1
Dawn-Ojeda, A. A., Marín-Canul, J. E., Granados-Patrón, D. A., Cuevas-Carbonell, S. G., Mut-Martín, M. C., Pérez-Izquierdo, O., Santiago, G.-T., Góngora-Alfaro, J. L., & Aranda-González, I. I. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.10.015 · Cited by 1
Iba, M., Lee, Y., Kwon, S., Horan-Portelance, L., Chang, K., Kim, M., Landeck, N., Rissman, R. A., Lee, S. J., You, S., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01564-4 · Cited by 3
Parkinson's disease: A chronic systemic inflammatory disorder
Khan, H., & Benskey, M. J. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-21992-4.00006-3 · Cited by 1
Dadhich, A., Verma, A. K., Dhar, I., Bhatt, S., Agarwal, N., & Sharma, M. M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119712 · Cited by 1
Molecular Pathogenesis and Pathophysiology of Parkinson’s Disease: New Targets for New Therapies
Castaño, J. G., González, C., Obeso, J. A., & Rodrı́guez, M. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737357-00026 · Cited by 1
Changes in the Immune System in Parkinson’s Disease
Romero‐Ramos, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1_150-1 · Cited by 1
James, B. C., Cox, A. J., & Lewohl, J. M. (2024) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15340 · Cited by 1
Immune response during idiopathic Parkinson's disease: From humans to animal models
Nissen, S. K., Ferreira, S. A., Klæstrup, I. H., & Romero‐Ramos, M. (2021) · International review of movement disorders · doi:10.1016/bs.irmvd.2021.08.006 · Cited by 1
Dagra, A., Miller, D. R., Shaerzadeh, F., Lin, M., Gopinath, A., Harris, S., Sorrentino, Z. A., Velasco, S., Alonge, A. R., Azar, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.30.437775 · Cited by 1
Garcia, P., Wemheuer, W. M., Huarte, O. U., Schmit, K. J., Masuch, A., Brioschi, S., Weihofen, A., Koncina, E., Coowar, D., Heurtaux, T., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.05.237750 · Cited by 2
Yanamandra, K. (2010) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Developing a neuroprotective therapy for Parkinson’s and Huntington’s diseases
Kazantsev, A. G. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.2.159
Quantitative Evaluation of Microglial Activation and Vascularization in Suicide
Schnieder, T. P. (2014) · CUNY Academic Works (City University of New York)
The Neuroprotective Potential of STN DBS and the Role of BDNF
Fischer, D. L. (2015) · Michigan State University Libraries · doi:10.25335/m5s778
Estudo das alterações motoras e comportamentais induzidas por rotenona em ratos machos e fêmeas
Ferreira, F. F. (2015) · UFPR Digital Collection (Federal University of Paraná)
Neural Substrates of Parkinson's Disease
Koshimori, Y. (2016) · TSpace (University of Toronto)
Miller, R. L. (2007) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/4764
O papel da microglia no modelo da doença de Parkinson induzido pela 6-hidroxidopamina.
Pereira, C. P. M. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2019.tde-18092019-145844
Microglial Mitophagy and Neurodegenerative Disorders
Oyindamola, E. A., Agyemang, M. K., Owusu-Sarfo, J., Yeboah, K. O., & Osafo, N. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-1317-0.ch004
Garcia, P., Wemheuer, W. M., Huarte, O. U., Schmit, K. J., Masuch, A., Brioschi, S., Weihofen, A., Koncina, E., Coowar, D., Heurtaux, T., et al. (2020) · doi:10.21203/rs.3.rs-29977/v1
New insights underlying the early events of dopaminergic dysfunction in Parkinson’s DiseasePreprint
Cruz, H. L. D., Cruz, E. L. D., Zurhellen, C., York, H. T., Baun, J. A., Cruz, J. L. D., & Cruz, J. S. D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.27.313957
Immunoinflammatory Aspects of Parkinson’s Disease
Belova, O. V., Arefieva, T. I., & Moskvina, S. N. (2020) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-020-01014-w
Loike, J. D., Jackson-Lewis, V. R., & Przedborski, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_31
Changes in the Immune System in Parkinson’s Disease
Romero‐Ramos, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_150
Involvement of Innate and Adaptive Immunity in Parkinson's Disease
Asai, H. (2017) · Journal of Neurology & Stroke · doi:10.15406/jnsk.2017.06.00188
Animal Models and the Pathogenesis of Parkinson's Disease
Castaño, J. G., Iglesias, T., & de Yébenes, J. G. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781849731843-00113
Rungruang, P., Sansri, V., & Sroyraya, M. (2024) · Neuroscience Research Notes · doi:10.31117/neuroscirn.v7i1.271
Role of microbiota gut–brain axis in Parkinson's disease
Mansuri, R., Dhanawat, M., Patel, S., Garima, G., & Diwan, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21680-0.00003-1
Modulation of microglia-T cell interaction as treatment of Parkinson's disease
Szklany, K. (2013) · Utrecht University Repository (Utrecht University)
Stoll, A. C., Kemp, C. J., Patterson, J. R., Kubik, M., Kuhn, N. C., Benskey, M. J., Duffy, M. F., Luk, K. C., & Sortwell, C. E. (2024) · Figshare · doi:10.6084/m9.figshare.26712368
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.26645842
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.26645827
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.26645830
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.26645824
Additional file 2 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331727
Bathe, T., Hery, G. P., Villareal, J. A. B., Phillips, J. L., Cohen, E. M., Sharma, R. V., Tsering, W., & Prokop, S. (2024) · Figshare · doi:10.6084/m9.figshare.26702602
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.26645818
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2023) · Figshare · doi:10.6084/m9.figshare.24647135
Stoll, A. C., Kemp, C. J., Patterson, J. R., Kubik, M., Kuhn, N. C., Benskey, M. J., Duffy, M. F., Luk, K. C., & Sortwell, C. E. (2024) · Figshare · doi:10.6084/m9.figshare.26712371
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.26645812
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.26645821
Additional file 1 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331724
Additional file 3 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331730
Bathe, T., Hery, G. P., Villareal, J. A. B., Phillips, J. L., Cohen, E. M., Sharma, R. V., Tsering, W., & Prokop, S. (2024) · Figshare · doi:10.6084/m9.figshare.26702596
Stoll, A. C., Kemp, C. J., Patterson, J. R., Kubik, M., Kuhn, N. C., Benskey, M. J., Duffy, M. F., Luk, K. C., & Sortwell, C. E. (2024) · Figshare · doi:10.6084/m9.figshare.26712374
van Wetering, J., Geut, H., Bol, J. G. J. M., Galis, Y., Timmermans, E., Twisk, J. W. R., Hepp, D. H., Morella, M. L., Pihlstrøm, L., Lemstra, A. W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26716930
Stoll, A. C., Kemp, C. J., Patterson, J. R., Kubik, M., Kuhn, N. C., Benskey, M. J., Duffy, M. F., Luk, K. C., & Sortwell, C. E. (2024) · Figshare · doi:10.6084/m9.figshare.26712380
Additional file 4 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331733
Bathe, T., Hery, G. P., Villareal, J. A. B., Phillips, J. L., Cohen, E. M., Sharma, R. V., Tsering, W., & Prokop, S. (2024) · Figshare · doi:10.6084/m9.figshare.26702599
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.24647350
Bérard, M., Martínez-Drudis, L., Sheta, R., El-Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.26645836
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.26645815
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.26645839
Bérard, M., Martínez-Drudis, L., Sheta, R., El‐Agnaf, O. M. A., & Oueslati, A. (2024) · Figshare · doi:10.6084/m9.figshare.26645833
Stoll, A. C., Kemp, C. J., Patterson, J. R., Kubik, M., Kuhn, N. C., Benskey, M. J., Duffy, M. F., Luk, K. C., & Sortwell, C. E. (2024) · Figshare · doi:10.6084/m9.figshare.26712377
Metadata
- Authors
- Croisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Graeber, Manuel B
- ORCID
- Dexter, David T
- Venue
- Journal of Neuroinflammation
- Published
- 2005-06-03
- Volume
- 2
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1742-2094 (ISSN-L)
- PMC
- PMC1177985
- OpenAlex
- W1822935226
- Cited by
- 414
- References
- 34
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 44 · 2023: 24 · 2022: 25 · 2021: 38 · 2020: 44 · 2019: 18 · 2018: 22 · 2017: 15 · 2016: 13 · 2015: 19 · 2014: 18 · 2013: 19 · 2012: 11
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Neuroinflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Parkinson's UK (G-4028)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, microglial activation, substantia nigra, MHC class II expression, CD68, microglial phagocytosis, neuroinflammation, disease duration, neuronal loss, postmortem brain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
